Our findings support the potential role of HMGA2 as a novel target for cisplatin resistance and suggest the feasibility of combining cisplatin and HMGA2 inhibition for the improved chemotherapy of cervical cancer. This evidence concerns the gene HMGA2 and cervical carcinoma.